Drug Profile


Alternative Names: Hepatitis-B-MAb; Human anti-Hep B; OST 577; Ostavir; Ostavir human anti-hepatitis B antibody

Latest Information Update: 22 May 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer PDL BioPharma
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunostimulants; Surface antigen inhibitors; Viral antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hepatitis B

Most Recent Events

  • 22 May 2001 No-Development-Reported for Hepatitis B in European Union (IV)
  • 22 May 2001 No-Development-Reported for Hepatitis B in Israel (IV)
  • 22 May 2001 No-Development-Reported for Hepatitis B in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top